This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lev, D. Articles by Pollock, R. E. Search for Related Content PubMed PubMed Citation Articles by Lev, D. Articles by Pollock, R. E.

Optimizing Treatment of Desmoid Tumors

Dina Lev, Dhanasekaran Kotilingam, Caimiao Wei, Matthew T. Ballo, Gunar K. Zagars, Peter W.T. Pisters, Alexander A. Lazar, Shreyaskumar R. Patel, Robert S. Benjamin, Raphael E. Pollock

From the Departments of Cancer Biology, Radiation Oncology, Surgical Oncology, Pathology, and Sarcoma Medical Oncology, and the Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Dina Lev, MD, Department of Cancer Biology, Unit 1104, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: dlev{at}mdanderson.org

Purpose: This study compared a large series of desmoid patients treated at a single institution to a previously published series from the same institution to determine if patient population characteristics, treatment approaches, and clinical outcomes had undergone change over the two study periods.

Materials and Methods: Data from a prospective soft tissue tumor database was used to analyze clinical courses of 189 desmoid patients treated at The University of Texas M.D. Anderson Cancer Center (UTMDACC) from 1995 to 2005 as compared with 189 UTMDACC desmoid patients treated between 1965 and 1994.

Results: A nearly three-fold increase in annualized UTMDACC desmoid referral volume with significantly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the most recent study period. Significantly increased systemic therapy use and decreased reliance on surgery alone was observed more recently. While the recent series patients had higher rates of macroscopic residual disease and equivalent rates of positive microscopic margins after definitive surgery, the estimated 5-year local recurrence rate of 20% was improved compared with the 30% rate observed in the earlier series.

Conclusion: Increased awareness of the complex multidisciplinary management needed for desmoid tumor control may underlie significantly increased numbers of referrals to UTMDACC, especially primary untreated desmoids. Increased neoadjuvant treatments may be associated with improved desmoid patient outcomes. These trends should be supported, particularly if personalized molecular-based therapies are to be rapidly and effectively deployed for the benefit of those afflicted by this rare and potentially debilitating disease.

Supported in part by the Desmoid Tumor Research Foundation.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				E. S. McDonald, E. S. Yi, and D. E. Wenger Best Cases from the AFIP: Extraabdominal Desmoid-type Fibromatosis RadioGraphics, May 1, 2008; 28(3): 901 - 906. [Full Text] [PDF]